Par Pharmaceutical, Inc. et al. vs. Novartis AG
Explore the PTAB proceeding IPR2016-01059 filed by Par Pharmaceutical, Inc. et al. on 2016-05-17. This includes filing dates, application numbers, tech centers, patent numbers, and current case status.
Proceeding Overview
Proceeding Number
IPR2016-01059
Filing Date
2016-05-17
Accorded Filing Date
2016-05-17
Institution Decision Date
2016-10-27
Last Modified Date
2022-10-10
Proceeding Type
IPR
Termination Date
β
Trial Status
Institution Denied
Parties & Counsel
Petitioner
Par Pharmaceutical, Inc. et al.
Represented By
Brown, Danielet alPatent Owner / Respondent
Novartis AG
Represented By
Kallas, Nicholaset alPatent Information
Tribunal & APJ Panel Intelligence
Tribunal
Patent Trial and Appeal Board (USPTO)
Technology Center
TC 1200
Decisions Rendered
1 Total
Proceeding Status
Institution Denied
Administrative Patent Judges (APJ Panel)
Board Decisions & Rulings (1)
Global Patent Family Cross-Litigation Radar
CasLoc 360Β° Radar 5 Family MembersMulti-jurisdiction dispute tracking across USPTO PTAB, U.S. Federal Courts, Unified Patent Court (UPC), and EPO Oppositions
| Jurisdiction | Publication Number | Relationship | Official Record |
|---|---|---|---|
| πΊπΈ United States | Asserted | Asserted Patent | View Official Patent → |
| π¬π§ United Kingdom | United Kingdom Counterpart | View Official Patent → | |
| π¬π§ United Kingdom | United Kingdom Counterpart | View Official Patent → | |
| π PCT International (WIPO) | PCT World Application | View Official Patent → | |
| πΊπΈ United States | US Continuation / Sibling | View Official Patent → |
Breckenridge Pharmaceutical, Inc. v. Novartis AG
Roxane Laboratories, Inc. et al. v. Novartis AG
BRECKENRIDGE PHARMACEUTICAL, INC. v. Novartis AG
Par Pharmaceutical, Inc. et al. v. Novartis AG
Novartis Pharmaceuticals Corporation v. Mylan Pharmaceuticals Inc.
Novartis Pharmaceuticals Corporation v. Breckenridge Pharmaceutical Inc.
Novartis Pharmaceuticals Corporation v. Par Pharmaceutical Inc.
Novartis Pharmaceuticals Corporation v. Breckenridge Pharmaceutical Inc.